Cancer NetworkOriginal article
<![CDATA[Extended Belantamab Mafodotin Dosing Eases Ocular Function in DREAMM-9]]>
Phase 1positivebelantamab mafodotinPositive
AI Analysis
Summary
Extended belantamab mafodotin dosing intervals demonstrated maintained vision-related function in the phase 1 DREAMM-9 study, suggesting improved tolerability for the multiple myeloma therapy.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Extended dosing intervals maintained vision-related function
Importance:5/10
Sentiment:
0.60
belantamab mafodotinDREAMM-9ocular toxicitydosing optimizationphase 1
Read the original article
Published by Cancer Network on September 29, 2026 5:00 PM